A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

BACKGROUND: Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qilin, Ding, Yiling, Shu, Yamin, Chen, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416473/
https://www.ncbi.nlm.nih.gov/pubmed/37568126
http://dx.doi.org/10.1186/s12885-023-11201-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416473/
https://www.ncbi.nlm.nih.gov/pubmed/37568126
http://dx.doi.org/10.1186/s12885-023-11201-w

Ejemplares similares